Agenus to Participate in B. Riley Healthcare Conference

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming B. Riley Virtual Healthcare Conference on January 18^th. The fireside chat will take place at 3:00 p.m. ET on January 18^th.

To access this event, please RSVP to your B. Riley Securities sales representative. Following the event, a replay of the fireside chat will be posted to the company’s website at https://investor.agenusbio.com/events-and-presentations.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240104722958/en/

at the time of publication of the news with a raise of +0,86 % to 0,707 on Tradegate stock exchange (04. Januar 2024, 12:34 Uhr).